ArticleClinical and translational medicine2017
Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?
Article in Clinical and translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.International journal of molecular sciences · 2024Article
- Liquid biopsies to occult brain metastasis.Molecular cancer · 2022Review
- Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods.Lung cancer management · 2019Article
- Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer.Thoracic cancer · 2019Article
- Article
- EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCAREJournal of Cancer · 2019Article
- Scar tissue to lung cancer; pathways and treatment.Journal of Cancer · 2019Review
- Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy.Translational lung cancer research · 2018Article
- Psoriatic arthritis due to nivolumab administration a case report and review of the literature.Respiratory medicine case reports · 2018Article
- Comparison of detection methods ofOncoTargets and therapy · 2018Article
- Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?Journal of thoracic disease · 2017Article
- Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.Respiratory medicine case reports · 2017Article
- EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.Respiratory medicine case reports · 2017Article
- Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.Respiratory medicine case reports · 2017Article
- "Liquid elbows" due to afatinib administration.Respiratory medicine case reports · 2017Article
- Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.Respiratory medicine case reports · 2017Article
- Targeted Lung Cancer Treatments and Eye Metastasis.Medical hypothesis, discovery & innovation ophthalmology journal · 2017Review
- Second-line afatinib administration in an elderly patient with squamous cell carcinoma.Therapeutics and clinical risk management · 2017Article
- Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.Respiratory medicine case reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is still the leading cause of death among all cancers. During the last 15 years, pharmacogenomics of lung cancer have established targeted therapy with tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) positive patients in adenocarcinoma or mixed adenosquamus lung cancer patients. However; while novel drugs are released in the market, at the same time novel mutations are observed after tyrosine kinase inhibitor administration. Recently the novel mutation T790 was observed and is highly prevalent in patients already treated with a TKI. A new drug targeting this mutation is already on the market, however; the most important factor for successful treatment in these patients, is adequate tissue re-sampling so that novel mutations can be detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.